Startups
Edit
Respicardia
http://www.respicardia.com/Last activity: 20.12.2017
Active - Reference to Central Sleep Apnea (CSA) Treatment
Founded in 2006 and acquired by ZOLL in 2021, ZOLL Respicardia is a leader in innovative technologies that address the unmet needs of people with Central Sleep Apnea (CSA). CSA results from the brain’s inability to send appropriate signals to the respiratory muscles to stimulate breathing during sleep. CSA is a serious breathing disorder that disrupts the normal breathing pattern and negatively affects quality of life and overall health. The remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for people with CSA.
Overview
Location
United States, Minnesota, Minnetonka
Total raised
$64.5M
Founded date
2006
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Aug 6, 2012 | Funding round | $6M |
Mentions in press and media 9
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 18, 2017 | Respicardia Closes $58.5M Financing | Respicardia, Inc., a Minnetonka, Minn.-based private medical technology company, closed a $58.5m financing. The round was led by Zoll Medical Corporation, a manufacturer of medical devices and related software solutions, with participation ... |
| Oct 31, 2014 | Funding Roundup: Which biotech, medtech and healthIT startups got investments this week? | $33 million in equity raised, closing out a $48 million Series E round The funding will bring Aileron candidate ALRN-6924 – a drug that works to activate a solid tumor suppressor protein called p53 – to clinical trial. The company says its ... |
| Oct 28, 2014 | Sleep apnea startup raises $25M, largely from Italian medtech co. | The device has been cleared for sale in Europe starting next year – having received a CE mark in 2010 – and Respicardia’s in the process of winning over U.S. regulatory approval. It’s currently in the midst of an IDE trial. Promoted Covid-1... |
| Nov 12, 2012 | Device startup aims to bring implantable solution to the problem of central sleep apnea | This novel therapy is meant to prove better clinical outcomes than the standard treatments, which include CPAP masks, drugs and other types of airflow devices. Labosky said that data from a feasibility study showed that the remede device is... |
| Aug 6, 2012 | Respicardia Receives $6M Senior Credit Facility from Ares Capital Corporation | Respicardia, Inc., a near Minneapolis, Minnesota-based early stage company developing a medical device targeted to improve respiratory and cardiovascular health by treating central sleep apnea, has received a $6m senior secured credit facil... |
| Device startup aims to bring implantable solution to the problem of central sleep apnea | For the past six years, Minnesota device startup Respicardia has been trying to commercialize a product that President and CEO Bonnie Labosky believes has no rival worldwide. It is an implantable device, the size of a pacemaker, that can be... | |
| Sleep apnea startup raises $25M, largely from Italian medtech co. | Most devices that treat sleep apnea are in the form of high-tech, oxygenated face masks – but a Minnesota startup is taking a different approach, building an implantable device that treats the common breathing disorder. Respicardia has rais... | |
| Funding Roundup: Which biotech, medtech and healthIT startups got investments this week? | Each week, many millions are invested into life sciences startups. There are so many that often, they get lost in the weeds. We’re keeping track for you – based on regulatory filings reported to the SEC. Here are the new funding notices fro... |
Reviews 0
FAQ about Respicardia
When was Respicardia founded?
Respicardia was founded in 2006.
How much funding has Respicardia raised?
Respicardia has raised $64.5M in total across 2 funding rounds.
What funding rounds has Respicardia raised?
Parsers VC lists 2 funding rounds of Respicardia, among them a funding round of $6M on Aug 6, 2012.
What has the press written about Respicardia?
Parsers VC has collected 9 articles mentioning Respicardia, among them “Respicardia Closes $58.5M Financing” (Dec 18, 2017) and “Funding Roundup: Which biotech, medtech and healthIT startups got investments this week?” (Oct 31, 2014).
Is Respicardia still active?
Yes, Respicardia is active; its latest activity on Parsers VC dates from Dec 20, 2017.